001454479 000__ 05003cam\a2200517\i\4500
001454479 001__ 1454479
001454479 003__ OCoLC
001454479 005__ 20230314003521.0
001454479 006__ m\\\\\o\\d\\\\\\\\
001454479 007__ cr\cn\nnnunnun
001454479 008__ 230209s2023\\\\sz\\\\\\o\\\\\001\0\eng\d
001454479 020__ $$a9783031195648$$q(electronic bk.)
001454479 020__ $$a3031195647$$q(electronic bk.)
001454479 020__ $$z3031195639
001454479 020__ $$z9783031195631
001454479 0247_ $$a10.1007/978-3-031-19564-8$$2doi
001454479 035__ $$aSP(OCoLC)1369264685
001454479 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dEBLCP
001454479 049__ $$aISEA
001454479 050_4 $$aQR46
001454479 08204 $$a616.9/041$$223/eng/20230209
001454479 24500 $$aMicrobiome in 3P medicine strategies :$$bthe first exploitation guide /$$cNadiya Boyko, Olga Golubnitschaja, editors.
001454479 264_1 $$aCham :$$bSpringer,$$c[2023]
001454479 264_4 $$c©2023
001454479 300__ $$a1 online resource (xv, 425 pages).
001454479 336__ $$atext$$btxt$$2rdacontent
001454479 337__ $$acomputer$$bc$$2rdamedia
001454479 338__ $$aonline resource$$bcr$$2rdacarrier
001454479 4901_ $$aAdvances in predictive, preventive and personalised medicine ;$$vvolume 16
001454479 500__ $$aIncludes index.
001454479 5050_ $$aChapter 1: Microbiome in the framework of Predictive, Preventive and Personalised Medicine -- Chapter 2: Artificial Intelligence-based Predictive, Preventive, and Personalised Medicine applied to Bacteraemia Diagnosis -- Chapter 3: Vaginal microbiome and its role in HPV induced cervical carcinogenesis -- Chapter 4: Microbiome in lean Individuals: Phenotype-specific Risks and Outcomes -- Chapter 5: Microbiome and Obesity -- Chapter 6: Pathophysiology-based approach for individualized use of probiotics and prebiotics for metabolic syndrome: implementing predictive, preventive, and personalized medical approach -- Chapter 7: Selection of prebiotic substances for individual prescription -- Chapter 8: Probiotic Administration for the Prevention and Treatment of Gastrointestinal, Metabolic and Neurological Disorders -- Chapter 9: Microbial therapy with indigenous bacteria. From idea to clinical evidence -- Chapter 10: Fecal microbiota transplantation in diseases not associated with Clostridium difficile: current status and future therapeutic option -- Chapter 11: Personalized microbiome correction by application of individual nutrition for type 2 diabetes treatment -- Chapter 12: Pro-, pre- and synbiotic supplementation and oxalate homeostasis in 3PM context: focus on microbiota oxalate-degrading activity -- Chapter 13: In vitro study of specific properties of probiotic strains for effective and personalized probiotic therapy -- Chapter 14: Probiotic concepts of predictive, preventive, and personalized medical approach for obesity: Lactic acid bacteria and Bifidobacteria probiotic strains improve glycemic and inflammation profiles -- Chapter 15: Oral Microbiome and Innate Immunity in Health and Disease: Building a Predictive, Preventive and Personalized Therapeutic approach.
001454479 506__ $$aAccess limited to authorized users.
001454479 520__ $$aThe book analyses microbiome-relevant findings focused on clinical needs providing the roadmap to implement recent achievements in the area representing a valuable contribution to the paradigm shift from reactive to predictive, preventive and personalised medicine (PPPM / 3PM) considered as the most advanced concept in medicine. Already well-acknowledged as well as future advantages of application of pre-, pro- and pharma-biotics are detailed in the book. Socio-economic impacts of the area are considered in the context of the entire spectrum of healthcare services from disease care provided to patients up to health care provided to persons in suboptimal health conditions. Innovative technologies including phenotyping, genotyping, individualised profiling, patient stratification, big data analysis, and multi-omics, amongst others are all involved in the book. The book is unique from view point of multi-professional expertise involved. International network presents more than 10 countries worldwide including Belgium, China, Germany, Israel, Ukraine and USA. The data presented are of great scientific value and of particular importance for educating a broad spectrum of professionals including researchers, healthcare givers, policy makers, business people, policy makers and general population.
001454479 588__ $$aDescription based on print version record.
001454479 650_0 $$aMedical microbiology.
001454479 655_0 $$aElectronic books.
001454479 7001_ $$aBoyko, Nadiya,$$eeditor.
001454479 7001_ $$aGolubnitschaja, Olga,$$eeditor.
001454479 77608 $$iPrint version:$$tMICROBIOME IN 3P MEDICINE STRATEGIES.$$d[Place of publication not identified] : SPRINGER INTERNATIONAL PU, 2022$$z3031195639$$w(OCoLC)1346069909
001454479 830_0 $$aAdvances in predictive, preventive and personalised medicine ;$$vv.16.
001454479 852__ $$bebk
001454479 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-19564-8$$zOnline Access$$91397441.1
001454479 909CO $$ooai:library.usi.edu:1454479$$pGLOBAL_SET
001454479 980__ $$aBIB
001454479 980__ $$aEBOOK
001454479 982__ $$aEbook
001454479 983__ $$aOnline
001454479 994__ $$a92$$bISE